Ogivri: payments to doctors
Payments that named Ogivri as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $159K
- Providers
- 925
- Transactions
- 1,477
- Average per transaction
- $108
The per-transaction average — $108 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 925 providers the average total is $172, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mylan Institutional Inc. | $102,516 | 64.3% |
| Mylan Inc. | $49,629 | 31.1% |
| Biocon Biologics Inc | $7,319 | 4.6% |